Pelthos Therapeutics Inc. (CHRO)
Jul 2, 2025 - CHRO was delisted (reason: merged into PTHS)
13.50
0.00 (0.00%)
Inactive · Last trade price on Jul 1, 2025
Channel Therapeutics Statistics
Total Valuation
CHRO has a market cap or net worth of $14.12 million. The enterprise value is $16.37 million.
| Market Cap | 14.12M |
| Enterprise Value | 16.37M |
Important Dates
The last earnings date was Tuesday, August 12, 2025, after market close.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +81.07% |
| Shares Change (QoQ) | +4.52% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 214,662 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | -2.17 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.81 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.11
| Current Ratio | 0.11 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.91 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -326.06% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 137.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.13M |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +46,775.00% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +46,775.00% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 45.16 |
| Average Volume (20 Days) | 759,448 |
Short Selling Information
The latest short interest is 76,911, so 11.66% of the outstanding shares have been sold short.
| Short Interest | 76,911 |
| Short Previous Month | 175,073 |
| Short % of Shares Out | 11.66% |
| Short % of Float | 37.06% |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.94M |
| Pretax Income | -9.04M |
| Net Income | -9.04M |
| EBITDA | n/a |
| EBIT | -8.94M |
| Earnings Per Share (EPS) | -$14.84 |
Balance Sheet
The company has $59,172 in cash and $2.30 million in debt, giving a net cash position of -$2.25 million.
| Cash & Cash Equivalents | 59,172 |
| Total Debt | 2.30M |
| Net Cash | -2.25M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -6.49M |
| Book Value Per Share | -9.65 |
| Working Capital | -6.49M |
Cash Flow
| Operating Cash Flow | -1.93M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CHRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -81.07% |
| Shareholder Yield | -81.07% |
| Earnings Yield | -64.00% |
| FCF Yield | n/a |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -6.92% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |